Category: Lab Tests and Imaging

New Iron-based Contrast Agent for Cardiac Fibrosis Diagnoses and Treats

Photo by Mart Production on Pexels

Researchers have developed a new iron-based contrast agent for magnetic resonance imaging that can be used for both diagnosis and treatment. In a study conducted on lab-grown human heart tissue, it was demonstrated that the contrast agent accumulates in the fibrotic tissue, that its signal intensity on the MRI image increases with disease severity, and that it slows disease progression.

The Biomolecular Nanotechnology research group led by Ikerbasque research professor Aitziber L. Cortajarena developed the iron-based contrast agent. The study, led by Cortajarena and conducted in collaboration with Ana Villar’s group at the Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC, UC-CSIC), has been published in Advanced Functional Materials. It paves the way for a possible alternative to gadolinium, the metal currently used in almost all contrast-enhanced MRI scans.

Cardiac fibrosis

Cardiac fibrosis is one of the main factors leading to heart failure, a disease that affects millions of people worldwide. There is currently no approved treatment specifically designed to slow down this condition. When the heart is damaged or under sustained strain (for example, after a heart attack or due to hypertension), a repair process begins, and the collagen production process is activated to repair and strengthen the tissue. However, this process often does not stop: the collagen continues to accumulate, the heart becomes stiff and finds it increasingly difficult to fill and pump the blood properly.

One of the techniques currently used for diagnosing fibrosis of the heart is MRI. In many cases, an intravenous contrast agent is administered to the patient, and is almost always based on gadolinium, which is retained in the damaged areas and lights them up. Although gadolinium works very well, it has various disadvantages. It is a metal that is foreign to the body. Its use is restricted in people with kidney failure, and it is known that small amounts of may be retained in different tissues for many years. This is especially concerning in patients who require repeated MRIs to monitor the progression of their disease, which is the case with cardiac fibrosis.

Iron atoms encapsulated in a custom-designed protein

For this reason, for many years researchers have sought to develop contrast agents based on iron, a metal that the body is familiar with and knows how to store and eliminate. However, there is a problem with existing iron-based contrast agents since, instead of illuminating the damaged area, they darken it, making it difficult to distinguish it in the images. Many of them have even been withdrawn from the market. The group led by Cortajarena, Scientific Director at CIC biomaGUNE, has been able to “overcome these problems by using designer proteins”, explains CIC biomaGUNE researcher Lydia Martínez Parra, lead author of the study.
Martínez adds, “the contrast agent consists of a specially designed protein that encapsulates and isolates minute clusters of iron atoms measuring approximately 1.4 nanometres (around 50 000 times thinner than a hair). It is also worth noting that this compound is safer for the body, is stable, releases very little iron and is of low toxicity to cells. Furthermore, it is easy and sustainable to manufacture, since it is produced in water, without toxic reagents or extreme conditions.”

A lab-grown fibrotic heart

The CIC biomaGUNE group has tested the efficacy of the contrast agent in cardiac tissue created with 3D tissue engineering using patients’ heart cells, developed by Ana Villar’s group (IBBTEC, UC-CSIC). These tissues replicate certain characteristics of cardiac fibrosis, such as the accumulation of collagen and increase in tissue stiffness, and enable new therapeutic strategies to be evaluated in more representative conditions than conventional cell cultures.

Thus, the research team has verified that the contrast agent moves towards and accumulates predominantly in the fibrotic tissue, that the signal on the MRI increases with the severity of the fibrosis, and that it slows its progression since it reduces the production and storage of collagen and prevents the tissue from becoming stiff. “That is, as well as indicating where the damage is, this material shows antifibrotic activity in the models studied”, says research professor Cortajarena. This is a ‘theranostic’ agent that offers diagnosis and treatment in the same material.”

Martínez points out that “this new compound enables the achievement of a contrast in magnetic resonance imaging comparable to that of gadolinium-based agents. It also retains this capacity in both magnetic fields commonly used in clinical practice and stronger magnetic fields used in preclinical research.” The compound formed by the iron atoms encapsulated by the protein make the tissue appear bright on the MRI.

The team behind the study affirms that “there’s still a way to go to reach the patient. For now, this new contrast agent has been tested in cells and human tissue in the laboratory. The next step will be to study it so that it can be used in clinical practice, to see how it is distributed and eliminated from the body and how it behaves on a real cardiac scanner. Our goal is that, in the future, patients with cardiac fibrosis, including those who cannot receive gadolinium, can have a safer imaging test that also forms part of their treatment.

Source: CIC biomaGUNE

Breakthroughs in Non-invasive Liver Testing Promise Fewer Biopsies

Two international studies have show that non-invasive tests can accurately diagnose and measure liver disease severity, reducing the need for biopsy. Published in The Lancet and Nature Medicine, the studies form part of the LITMUS programme, the largest international effort to evaluate diagnostic tools for metabolic dysfunction-associated steatotic liver disease (MASLD), including its more severe form, metabolic dysfunction-associated steatohepatitis (MASH).

To date, liver biopsy has been considered the reference standard for definitively distinguishing MASLD from active MASH with fibrosis, but its invasive nature carries procedural risks and it is resource-intensive. The diagnostic reliability of liver biopsy is limited by sampling error and by variability in tissue adequacy, with interobserver variability adding to challenges in histological interpretation.

The main LITMUS Study, published in The Lancet, assessed blood tests and ultrasound-based liver stiffness measurements in more than 1500 patients – the largest international study of its kind.

The companion LITMUS Imaging Study, published in Nature Medicine, examined advanced MRI and elastography techniques in more than 350 patients.

Together, these two studies give us the most complete picture yet of which diagnostic tests work for liver disease, and how to combine them into a pathway health systems can easily implement

Professor Quentin Anstee

New benchmark in liver disease diagnosis

Professor Quentin Anstee, Ruth & Lionel Jacobson Chair in Personalised Medicine at Newcastle University, and Honorary Consultant Hepatologist at Newcastle Hospitals NHS Foundation Trust, is joint senior author of both studies and the LITMUS consortium coordinator.

He said: “Together, these two studies give us the most complete picture yet of which diagnostic tests work for liver disease, and how to combine them into a pathway health systems can easily implement.

“For advanced liver scarring and cirrhosis, we now have tools good enough to use with real confidence. Detecting active liver inflammation remains more challenging, but promising non-invasive tests are becoming available.”

MASLD affects up to one in three adults worldwide and as many as seven in 10 people living with obesity or type 2 diabetes.

As the first licensed drug treatments for MASH enter clinical practice, there is growing demand for accurate, non-invasive ways to diagnose and monitor disease.

Together, the studies assessed dozens of blood, imaging and elastography-based biomarkers – covering both state-of-the-art and routine diagnostic tests that are already used by doctors – comparing their accuracy to liver biopsy, read by expert pathologists.

The findings provide robust, prospective and independent evidence from large multinational patient cohorts, offering what researchers believe are the most realistic benchmarks yet for non-invasive liver disease testing.

The key findings of the studies are:

  • For advanced liver fibrosis and cirrhosis, the SOMAScan proteomic panel, MR elastography (MRE) and FibroScan-based elastography tools, including the Agile 3+ score, delivered the highest levels of diagnostic accuracy.
  • The ELF and ADAPT blood tests also exceeded predefined performance thresholds for detecting cirrhosis.
  • For identifying “at-risk MASH” – the group targeted in most clinical trials – only the SOMAScan panel met the predefined accuracy threshold.
  • A simple and inexpensive gamma-GT blood test outperformed the widely used FIB-4 score as a first-line assessment tool and could be followed by FibroScan or ELF testing to confirm disease severity in routine care.

Targeting the right patients for referral to specialist liver care

The findings support a simplified diagnostic pathway that, after further validation, could be adopted across healthcare systems: use gamma-GT as an initial screening test, followed by ELF or FibroScan for patients requiring further assessment, with advanced imaging reserved for specialist care.

This approach could help more patients receive an accurate diagnosis without undergoing an invasive liver biopsy while ensuring specialist resources are targeted where they are most needed.

The findings also have important implications for MASH clinical trials.

Because regulators require confirmation of “at-risk MASH” for enrolment in late-stage studies, liver biopsy is likely to remain necessary for now. However, the strong performance of SOMAScan highlights its potential for future adoption.

The LITMUS Imaging Study also demonstrated that elastography techniques performed well for detecting advanced fibrosis and cirrhosis, with MRE outperforming FibroScan-based liver stiffness measurements.

Reference:

Non-invasive tests in Metabolic-dysfunction Associated Steatotic Liver Disease: The prospective, multi-centre LITMUS Study. The Lancet, 2026. Vali et al. DOI: 10.1016/S0140-6736(26)01145-1 

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD. Nature Medicine, 2026. Pavlides et al. DOI: 10.1038/s41591-026-04496-2

Source: Newcastle University

Ultrasound Brings Faster Diagnosis Closer to Home for Mpumalanga Patients

Almost 3000 scans performed in five months as Bophelo First Trust and Dis-Chem Better Tomorrow Starts Here strengthen diagnostic capacity across six public hospitals

Patients at five Mpumalanga hospitals are benefiting from faster diagnosis following the launch of a point-of-care ultrasound programme by Bophelo First Trust (BFT), a South African Public Benefit Organisation (PBO), in partnership with Dis-Chem. The initiative has so far trained 14 clinicians and deployed 10 portable ultrasound machines, enabling surgical, emergency and trauma teams to scan patients at the bedside and reduce the need for referrals to other facilities.

BFT’s model strengthens existing public health systems through structure, continuity and measurable impact. It enables targeted operational support programmes that help unlock underutilised healthcare infrastructure and increase patient access to care.  Through collaborative partnerships, it develops and implements scalable healthcare support initiatives focused on reducing surgical backlogs, increasing procedural throughput, expanding access to diagnostic capability, strengthening operational healthcare capacity and supporting long-term public-sector sustainability.

Uptake has been strong since the programme launched in May, says BFT CEO Dr Mark Wadley. “Targeted operational interventions have the potential to unlock additional healthcare capacity within existing public-sector infrastructure. With point-of-care ultrasound, a trained clinician can perform a focused scan beside the patient and interpret the findings in real time. This means patients can be assessed sooner and, where appropriate, avoid the need to travel elsewhere for imaging.”

The programme addresses a significant diagnostic gap in a province serving close to five million people. Since May, clinicians had performed 2,865 scans covering abdominal, vascular, trauma and musculoskeletal applications.

“Better Tomorrow Starts Here addresses pressing societal health challenges across South Africa and looks to find practical ways to improve access to quality care,” says Joshila Shiba, Dis-Chem’s Head of Health Equity and Sustainability. “This programme shows how targeted, practical interventions can unlock additional healthcare capacity within existing public-sector infrastructure and aligns with Dis-Chem’s purpose of increasing access to quality healthcare access. We want to help build, support and strengthen healthcare ecosystems across South Africa.”

“Our Better Tomorrow Starts Here initiative reflects our commitment to societal health challenges by aligning our business goals with sustainable development in South Africa and connecting our overarching “Better Health Starts Here” purpose with a broader commitment to contributing positively to the country’s future.”

Dr David Marubini, one of the 14 clinicians trained through the programme, says access to ultrasound is particularly valuable in surgical care, where delays in diagnosis can affect treatment decisions.

“Before we had ultrasound in our department, a patient arriving with severe abdominal pain or injuries from a road accident often had to wait before we could see what was happening internally. Sometimes they had to be transferred to another hospital first,” says Dr Marubini.

“Now I can scan at the bedside within minutes and answer urgent questions straight away. Is there internal bleeding? Does this patient need to go to theatre now, or can we safely manage them here? It doesn’t replace a full radiology service, but it allows us to make decisions sooner and with greater confidence.”

Dr Wadley says the initiative could provide a scalable model for strengthening diagnostic capacity in public hospitals across South Africa.

“Clinician participation is expanding and more hospitals are showing interest. The next phase will focus on improving how the clinicians’ ultrasound images and video clips are stored and uploaded to the cloud. This will support AI-assisted quality assurance and training, helping to maintain scanning standards as more clinicians are trained. In turn this will further strengthen diagnostic capacity in the province” concludes Dr Wadley.

Study Investigates Using AI to Cut Radiation Dose in Heart Scans

Source: Wikimedia CC0

A new study at The University of Texas at Arlington could help substantially reduce the amount of radiation heart patients receive during imaging procedures without sacrificing diagnostic accuracy.

The study, led by Mingwu Jin (professor of physics), will focus on computed tomography angiography (CTA), an advanced imaging test that noninvasively assesses coronary artery disease. CTA combines a CT scan with iodine contrast dye injected into a patient’s vein to create 3D images of blood vessels and surrounding tissues. Doctors can use CTA to detect aneurysms, narrowed or damaged blood vessels, blood clots, tumours and other conditions.

The project is funded by a three-year, $579 745 grant from the National Heart, Lung, and Blood Institute. The project is titled “Deep leaRning-bAsed reConstruction (DRAC) for Multi-Phase Cardiac CT Angiography.”

Multi-phase coronary CTA (MP-CCTA) captures images at multiple points during the heartbeat, providing doctors with more information and helping reduce blurring caused by the heart’s movement. The drawback is that collecting images across multiple phases exposes patients to more radiation than a single-phase scan. Dr Jin’s research aims to substantially reduce that radiation exposure while preserving the quality and diagnostic value of the images.

“Lowering the radiation dose in medical imaging has been vigorously pursued due to imaging prevalence and potential cancer risk of ionising radiation,” Jin said. “Although notable progress has been made by developing advanced reconstruction methods, the dose reduction potential is far from its limit.”

CT scans use reconstruction methods to turn raw data collected during a scan into images doctors can interpret. One advanced approach is model-based iterative reconstruction (MBIR). Another is 4D reconstruction, which adds the dimension of time to standard 3D imaging. In cardiac imaging, this technique can capture clear views of fast-moving heart valves and coronary arteries while reducing motion artefacts.

Jin said that recent breakthroughs in deep learning provide an unprecedented opportunity to substantially lower radiation doses by combining MBIR with information learned from a large database of high-quality MP-CCTA images. The resulting 4D DRAC method would reconstruct a patient’s images using not only data from that individual scan, but also information learned from a much larger collection of images.

Jin said the project could substantially lower the radiation dose needed for MP-CCTA, potentially improving its use in detecting the narrowing of coronary arteries and monitoring the progression of high-risk plaque. He said the 4D DRAC methods could also be applied to other dynamic CT scans.

To test the hypothesis, Jin and his team will:

  1. Build a synthetic patient library using computational human models based on retrospectively collected MP-CCTA data from real patients.
  2. Develop 3D and 4D deep-learning methods that combine CT imaging physics with features learned from the high-quality patient data.
  3. Determine the lowest radiation dose that can be used without compromising diagnostic accuracy. The team will evaluate diagnostic accuracy using a computer model designed to mimic how a radiologist assesses an image, then validate the results through a small-scale study involving human observers.

The Mayo Clinic in Rochester, Minnesota, will provide MP-CCTA patient data for the study.

“This award reflects the high quality of Dr Jin’s research and the strength of his proposed ideas,” said Alex Weiss (professor of physics and former department chair). “I know a great deal of work goes into preparing a successful proposal of this kind. This is a significant achievement for Dr Jin and a major benefit to our department.”

Graduate students Noor Rasel and Darnisha Langlais will work with Jin on the project. The grant will also allow Jin to hire undergraduate students in the summers, providing them with research opportunities to apply AI techniques to medical imaging.

Source: University of Texas at Arlington

A Few Licks of this Candy-coated Device Measures Medication Levels in Saliva

A few licks of the lollipop-like prototype collects enough saliva to test for paracetamol levels.

The red, peach-flavoured candy coating on Lollylab stimulates saliva production, and a sensor at the bottom analyses it for paracetamol. Adapted from ACS Sensors 2026, DOI: 10.1021/acssensors.6c00691

What if checking medication levels were as simple as enjoying a lollipop? A candy-coated device, called Lollylab, could provide the answer. In ACS Sensors, researchers describe how the lollipop’s stem transfers saliva to a sensor that measures acetaminophen levels. In an initial test, a peach-flavoured prototype reliably detected the pain reliever in six people’s saliva in less than two minutes. Participants also found it more comfortable and easier to use than traditional collection swabs.

Taking more than the maximum recommended dose of paracetamol can cause serious side effects, such as liver damage. This is especially concerning for children who can be at risk of an unintentional overdose at low levels of the medication. Because paracetamol concentrations in saliva closely reflect those in blood, Sina Khazaee Nejad, Maral Mousavi, and colleagues thought saliva could be a simple, noninvasive way to monitor the medication’s levels. 

Mousavi says they were inspired by the saliva sampling system CandyCollect — a lollipop-like device meant to replace throat swabs — but those specimens need to be analysed elsewhere. In this work, the researchers wanted to create a miniature laboratory-on-a-lollipop, or Lollylab. “By turning a familiar object like a lollipop into both a saliva collection device and a sensor, Lollylab can collect the sample and perform the measurement directly at the point of care,” says Nejad, the first author of the paper.

Lollylab is built from two plastic pieces (each with a round end and a thinner stem) snapped together, with holes at the top for saliva to enter through. The team coated the top of the device with a red, peach-flavoured edible candy shell, which did not interfere with measurements. Saliva flows through the glass fibre paper-lined lollipop stem toward a graphene sensor at the bottom, which measures acetaminophen levels as changes in electrical current. The prototype device detected acetaminophen in both artificial and human saliva.

As proof of concept, six adults used Lollylab before and an hour after taking a standard adult dose of paracetamol (650 milligrams). The device reliably measured the drug in the participants’ saliva in less than two minutes, and they said it was easy to use and more comfortable than typical saliva swabs.

“The main takeaway is that diagnostic testing can be made much easier and more comfortable, especially for children,” says Nejad. Next, the researchers plan to validate Lollylab’s paracetamol measurements with more participants, including children, and develop it to detect other substances in saliva such as naturally occurring stress markers. “Our longer-term goal is to create a multi-assay platform capable of measuring several biomarkers, which could then be evaluated alongside acetaminophen [paracetamol] in larger clinical studies.”

Source: American Chemical Society

Blood Test Trends may Help Identify Patients at Increased Risk of Cancer

Among patients with unexplained weight loss, changes over time in routine blood test results were associated with overall and site-specific cancer diagnoses

Photo: Pixabay

Blood test trends alongside unexplained weight loss can improve triage for cancer testing, according to a study by Brian Nicholson and colleagues from the University of Oxford, UK, published September 17th in the open access journal PLOS Medicine.

Abnormal blood test results, such as low haemoglobin or increased platelet counts, can provide clues about a patient’s risk of developing cancer. However, monitoring trends over repeat tests could provide further clues in some instances, by identifying cancer-related changes in blood test results that do not appear abnormal. Assessing patterns in blood test abnormalities and trends alongside unexplained weight loss could enhance cancer risk assessment and support earlier diagnosis.

In this study, researchers examined trends in blood test results among patients with unexplained weight loss, a common non-specific symptom associated with multiple cancer types. The goal was to determine whether trends in 26 commonly used blood tests in primary care could improve cancer risk stratification compared to abnormalities on single blood tests.

Among the more than 275 000 patients included in the study, nearly 14 000 were subsequently diagnosed with cancer within six months, allowing researchers to relate abnormalities on single tests and trends over repeat blood tests to cancer diagnosis. Overall, 23 blood test trends were associated with overall cancer risk. Several abnormalities were also associated with specific cancer types. After accounting for age and sex, several blood test trends were more discriminative for cancer diagnosis than individual abnormal test results. For example, trends in white blood count and neutrophils were linked to lung cancer while trends in red blood cell count, haematocrit, and platelet-to-lymphocyte ratio were associated with prostate cancer.

The findings suggest that monitoring changes in routine blood test results in patients with unexplained weight loss could identify patients in primary care who would benefit from additional cancer testing.

Author Brian Nicholson adds, “We show how blood test results are made more accurate for cancer by adding patient age and sex. This relatively simple calculation could easily be performed at the laboratory.”

Author Pradeep Virdee states, “In some instances, monitoring how a patient’s blood test results change over time could offer further value. We plan to assess how well blood test abnormalities and trends inform cancer risk in patients with other types of non-specific symptoms, such as fatigue and vomiting.”

Provided by PLOS

Longer Intervals Between Colonoscopies May Be Safe

Photo by Tima Miroshnichenko

Patients who have had high-risk polyps removed from their bowel can probably wait five years, rather than three, until their next colonoscopy without increasing their risk of colon and rectal cancer. This is shown by two new studies published in the New England Journal of Medicine, in which researchers from the Karolinska Institutet have participated. The findings, from ”Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal” and “Colorectal Cancer Risk among Patients with Serrated Polyps” could reduce the number of examinations and thus the burden on both patients and the healthcare system.

Every year, around 1.9 million people worldwide are diagnosed with bowel cancer. To prevent the disease, many countries have introduced screening programmes that enable more polyps to be detected and removed before cancer develops.

However, some patients are assessed as being at increased risk of developing new polyps or cancer and are therefore recommended to undergo regular follow-up colonoscopies. These examinations are resource-intensive for the healthcare system and can be perceived as burdensome for patients.

The first results from the European Polyp Surveillance (EPoS) study, a large randomised research project on follow-up after polyp removal, are now being presented. In the EPoS II study, 10 799 patients across eight European countries who had previously had high-risk adenomas – a type of polyp – removed were followed up. Participants were randomised to undergo their first follow-up colonoscopy after either three or five years.

Low risk in both groups

After five years of follow-up, the risk of colorectal cancer was very low in both groups. Among those who waited five years for their first check-up, 0.77 per cent developed cancer, compared with 0.82 per cent among those examined after three years. Nor did the researchers observe any clear differences in how far the cancer had progressed when it was detected.

At the same time, the longer follow-up interval meant that the number of colonoscopies fell sharply. During the follow-up period, nearly 4200 fewer examinations were carried out in the group that waited five years for their first follow-up.

”More than 99 per cent of patients did not develop colorectal cancer within five years of the polyps being removed. “The results suggest that we need to reassess when these patients should be called in for their next colonoscopy,” says Hans-Olov Adami, Professor Emeritus at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet, who coordinated the Swedish part of the research project.

At the same time, the researchers are presenting results from the parallel EPoS III study, which involved 1,861 patients with so-called serrated polyps, another type of polyp that can also be a precursor to cancer. In that group, too, the risk of cancer was low. After five years, around one per cent of the participants had developed colorectal cancer and none had died from the disease.

“The low risk of cancer was observed in both patients with high-risk adenomas and those with serrated polyps. This also underlines the importance of the first colonoscopy, as the studies are based on the polyps having been detected and completely removed,” says Hans-Olov Adami.

Source: Karolinska Institutet

How Paediatric Radiology Gives Answers when Children Cannot

Children are NOT small adults. They experience and express illness and injury very differently from adults. Which is why paediatric diagnostic imaging is a highly specialised field of medical imaging and is specifically designed for children, from birth to adolescence.

Dr Ebrahim Banderker, a paediatric radiologist at Red Cross War Memorial Children’s Hospital (RXCH), explains why children need a different approach to imaging and the role of radiology in children. He also talks about the success of a public-private initiative with SCP Radiology where he is a consulting radiologist.

Why is paediatric imaging so important?

Children are often unable to, or struggle to describe the nature of their discomfort, pain or symptoms clearly. Imaging helps doctors understand what is happening inside the body, when language and understanding are limited.

When we diagnose early, we are often preventing future pain, disability or developmental issues as well as reducing the anxiety of the family. 

What should parents know or understand about paediatric radiology?

Paediatric imaging is designed with the needs, safety and the specific conditions of children in mind. It is a tool for clarity, reassurance and early care. Our goal is to care for the child in their imaging journey and provide their doctors and families with clear answers they can trust.

How is paediatric radiology different from adult radiology?

  • The choice of the method of imaging is primarily based on how safe it is. The effects of radiation from X-rays and CT scans have a greater risk for a child than an adult – so ultrasound and MRI are preferred where possible.
  • Children are often afraid, unsettled because of pain and anxiety and may require sedation or anaesthesia to make them comfortable during the imaging process.
  • Paediatric imaging equipment, anaesthetic apparatus, monitoring and emergency equipment have to be adapted to children of different ages.

Do paediatric radiologist work directly with children and their parents?

Paediatric radiologists interact with the child and their caregivers far more often than adult radiologists interact with their patients. It is one of the most rewarding aspects of our work. Parents are generally more involved and can help the radiologist by confirming the history and symptoms. The radiologist in turn can reduce parent anxiety, explain the procedure and obtain consent where needed.

Please can you talk about radiation and safety in children – we know that one of the issues both parents and other adults have is safety and radiation?

Children have rapidly developing cells and tissues, often tightly packed together in small bodies and are considered to be 10-15 times more sensitive to radiation.  

The guiding principle of all radiation safety is ‘ALARA,’ which stands for ‘As Low As Reasonably Achievable’ or as we say, ‘when benefit clearly outweighs the risk.’  Ultrasound and MRI do not use radiation and these should be used where possible.

What injuries are commonly seen in children that require imaging?

Common injuries include those from motor vehicle accidents and particularly pedestrian accidents, fractures from falls or playing sport and unfortunately, increasingly from child abuse which is sometimes first identified by the radiologist.

Children’s bones are different from adults and have areas where the bone is still growing. These are called growth plates. Injuries to the growth plates require special care because they can affect how a bone develops and this impacts the overall growth of the child. 

Outside of injuries, paediatric imaging also looks at chest infections, abdominal pain, appendicitis, urinary tract problems and hip development in infants. Brain imaging may be used for seizures, headaches or developmental concerns. In essence, imaging can help us rule out serious causes quickly, which brings enormous reassurance to families.

Even for adults, radiology can be stressful and frightening – for children it must be worse.  How are children supported during scans?

Radiographers and radiologists are trained to work gently and calmly with children and parents are encouraged to be involved and ask questions. For example, when a child needs to be sedated for an MRI, the parent will stay with them until they are asleep. When children feel safe, the scan is quicker, easier and more accurate. The team ensures the child is warm and comfortable and the environment is child friendly with toys and reading material to distract patients and to keep them happy and engaged.

What developments in paediatric radiology do you feel are the most important – especially over the 5 years?

  • Digital radiography allows for digital manipulation of images improving image quality and accuracy. Retakes are reduced so there is less radiation involved
  • Ultrasound machines have improved in-depth visualisation of body parts, disease processes and blood vessels
  • CT scanners are faster and offer lower radiation dose options. There are scanners which can scan the entire body of a child in less than a second.  There is not even time to wriggle…
  • MRI imaging is developing at a galloping pace with faster scanning techniques and finer image detail
  • Functional MRI and the ability to do tissue sampling in cancer imaging, is opening many exciting new avenues. 

The scope of interventional radiology techniques (treating not just diagnosing) is expanding rapidly to make less invasive treatment possible, with less complications for patients and much shorter recovery times. Paediatric radiology increasingly includes minimally invasive procedures (image-guided drainages, biopsies, nephrostomies, angiography), which can shorten hospital stays and reduce surgical burden. 

Blood Tests Could Yield Even More Information About Cancer

A single blood test could in future provide a more comprehensive picture of cancer than current methods. In a review article published in the journal Genome Medicine, researchers at Karolinska Institutet describe how several different biological signals can be analysed simultaneously from the same blood sample to detect and monitor cancer diseases.

Researchers and clinicians currently use so-called liquid biopsies, in which material from tumours can be detected in the blood. The method is less invasive than traditional tissue samples and can be used to monitor disease progression over time. In the current review article, researchers summarise developments in a growing field of research in which several different molecular signals are combined in the same analysis. These signals may come, among other things, from free DNA and RNA in the blood, as well as from changes in the structure of the genome and chemical markers. 

The researchers call the approach ‘multifeature sequencing-based liquid biopsy’ (MSLB). The idea is not only to look for a single change linked to cancer, but to combine several types of information to provide a broader picture of the tumour’s characteristics. 

“By analysing several biological signals simultaneously from the same blood sample, we can potentially gain a more complete picture of the biology of cancer than by studying each signal separately,” says Mariano A. Molina Beitia, researcher at the Department of Laboratory Medicine, Karolinska Institutet. 

The article describes several research studies in which combinations of different signals have been used to detect cancer or monitor the disease over time. For example, analyses of DNA methylation, fragment size and chromosomal changes in blood have shown promising results for the early detection of several types of cancer. The researchers also describe how advanced bioinformatics methods and machine learning are used to interpret the large amounts of data generated. 

Challenges remain

At the same time, the researchers emphasise that the technology still faces several challenges. Many studies have been carried out in limited patient groups, and the results need to be confirmed in larger prospective studies. In addition, the methods are technically complex, and there are still no common standards for how the analyses should be performed and quality-assured across different healthcare centres. 

“For the technology to be widely used in healthcare, standardised workflows, independent validation and studies demonstrating the benefits of the analyses for patients are needed,” says Daniel Hagey at the Department of Laboratory Medicine and senior researcher in the study. 

The researchers believe that the first clinical applications will most likely be in monitoring cancer patients, assessing treatment effects and situations where repeated tissue samples are difficult to obtain. In the longer term, the method could contribute to a more integrated and dynamic picture of cancer development based on a simple blood sample. 

Source: Karolinska Institutet

New Method Distinguishes Between Healthy and Diseased Immune Cells in Blood Samples

Scanning electron micrograph of a T cell lymphocyte. Credit: NIH / NIAID

Researchers at Karolinska Institutet and SciLifeLab have developed a new method to analyse the condition of immune cells in the blood. The method has been tested on patients with atherosclerosis and can distinguish their immune cells from those of healthy individuals. The study is published in the journal Nature Nanotechnology.

The physical properties of immune cells, such as how the cell membrane is structured or how the mitochondria function, affect how the cells move, communicate, and respond to inflammation. These properties have previously been difficult to measure on a large scale.

Now, researchers have developed a method that measures multiple physical properties simultaneously in individual cells, across very large cell populations. The method is called spectral biophysical cytometry (SBC) and combines fluorescent nanosensors, which respond to the cells’ physical environment, with advanced flow cytometry, where thousands of cells are analysed one by one using laser light in a few minutes.

The researchers used the method to analyse immune cells in blood from 38 patients with atherosclerosis and 26 healthy control individuals.

“We show that immune cells in atherosclerosis have altered physical properties that can be measured directly in blood samples, without first needing to analyse genes or proteins,” says Erdinc Sezgin, researcher at SciLifeLab and the Department of Women’s and Children’s Health, Karolinska Institutet. “The method provides an integrated picture of the health status of the immune cells and can serve as a complement to more time-consuming and costly analyses.” 

May affect disease processes

The analyses revealed clear differences in, among other things, the organisation of cell membranes and mitochondrial function, particularly in different types of T cells. These changes could also be linked to alterations in the cells’ lipid composition and which genes were active.

“This suggests that the physical properties of cells are indications of health and important in disease processes in atherosclerosis and possibly also in other diseases,” says Erdinc Sezgin.

The study is a so-called proof-of-concept study, meaning an early step demonstrating that the principle works. The next step is to investigate the method in larger patient cohorts and in other diseases.

Source: Karolinska Institutet